FDA Accepts Investigational New Drug Application for Peanut Allergy Candidate Developed by COUR Pharmaceuticals

Today, COUR Pharma announced the U.S. Food and Drug Administration accepted its Investigational New Drug Application to initiate the first clinical trial for CNP-201, a nanoparticle immune-modifying drug candidate for peanut allergy.